Equine VEGF-A quantitates equine VEGF-A in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant equine VEGF-A.
Equine VEGF-A quantitates equine VEGF-A in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant equine VEGF-A.
VEGF (vascular endothelial growth factor), which is a homodimer glycoprotein bound to disulfide involved in 45 kDa angiogenesis, promotes tumour progression and metastases. VEGF has various effects on vascular endothelium, including the ability to promote endothelial cell viability, mitogenesis, chemotaxia and vascular permeability. VEGF's family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and PIGF. The VEGF and its receptor system have proven to be the fundamental regulators of cell signaling of langenogenicity. Most tumours have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine associated with this process. To date, 5 different VEGF isoforms have been described. These isoforms are generated following an alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine kinase flt-1 receptors (VEGFR-1) and flk-1/KDR (VEGFR-2 receptors), which have been expressed almost exclusively on endothelial cells. VEGF and its high affinity binding receptors, tyrosines kinases FLK1 and FLT1, are considered important for the development of embryonic vasculature. Studies have shown that an alternately spliced form of FLT1 produces a soluble protein, called sFLT1, which binds vascular endothelial growth factor with high affinity, acting as an inhibitor in angiogenesis. High levels of VEGF are associated with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy, skin changes), also known as Crow-Fukase syndrome, which affects several organs of the body.
Sensitivity
Sensitivity of the dosage: 4 pg/ml.
Measurement range
Dose range: 4 to 1,000 pg/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Reproducibility
Coefficient of intradose variation < 10%, interdose < 12%.
Samples
Sample type: Plasma, Serum, Surnatant (Serum volume, 50 μl; Plasma, 50 μl; Supernatant, 50 μl).
Technical specifications
| General |
| Brand | Invitrogen |
| Supplier ref. (Fisher Scientific) | 17884050 |
| Specifications |
| Accession number | angiogenic factor; ETID309976.16; eVEGF120; eVEGF164; homologue VEGF121 human; MGC70609; MVCD1; ovine vascular endothelial growth factor; RP1-261G23.1; nameless protein product; VAS; vascular endothelial growth factor; precursor of endoth growth factor |
| Dose range | 4 to 1000 pg/ml |
| Sensitivity of the dosage | 4 pg/ml |
| Conjugate | Biotin |
| Product type | ELISA |
| Type of sample | Plasma, Serum, Surnatant |
| For use with (equipment) | Colorimetric microplate reader |
| Genetic identification (Enter) | Q9GKR0 |
| Gene symbol(s) | VEGFA analysis |
| Coefficient of inter-dose variation | < 12% |
| Coefficient of intra-dose variation | < 10% |
| Contents of kits | 96-well pre-coated plate, standard, dosing diluent concentrate, biotinylated detection antibody, SAV-HRP, washing pad, chromogen, stop solution, adhesive plate lids |
| Marker or dye | HRP |
| Quantity | 10 x 96 tests |
| Regulatory status | Use exclusively for research |
| Target | VEGF analysis |
| Test time | 1 h 20 min |
| Physical characteristics |
| Volume of sample | Serum, 50 μl; Plasma, 50 μl; Supernatant, 50 μl |
| Storage and shipping |
| Storage conditions | 2°C to 8°C |
| Total duration of dosing | 4 h 45 min |
Origin and customs
| Manufacturer ref. | EE9RBX10 |
|---|
| Country of origin | United States |
|---|
| HS customs code | 3002 12 00 00 |
|---|
A question or a specific configuration?
Contact us for a quote.